Enterodes

Quick links to important sections

Enterodes

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enterodes

Property Description
Active ingredient Povidone Iodine
Pharmacological class Broad-spectrum Antiseptic
Form Solution, Gel, Ointment, or Spray
Common purpose Anti-infective cleansing
Origin Synthetic chemical complex

What Type of Medicine is Enterodes?

Enterodes refers to a medicinal preparation defined by its core active ingredient, Povidone Iodine, which is classified as a broad-spectrum antiseptic and a local anti-infective agent. The substance belongs to the category of iodophor solutions, stable chemical complexes designed to carry and efficiently release iodine. This identity is clinically recognized for its established effectiveness as an antimicrobial agent.

This pharmacological agent is utilized for the non-specific neutralization of a wide array of pathogens. The designation as an iodophor solution highlights its ability to deliver the active halogen in a more controlled, effective manner than older iodine preparations, which often carried a higher risk of local irritation.


Enterodes Composition: Is it Synthetic or Natural?

The active ingredient, Povidone Iodine, is a synthetic chemical complex, formed by stably binding Elemental Iodine (I2) to the polymer carrier, Polyvinylpyrrolidone (Povidone). This formulation is commonly prepared as an aqueous solution or a gel for application.

While Povidone Iodine is overwhelmingly used for topical administration (on skin or mucous membranes) in its antiseptic role, the trade name Enterodes has historically been associated with a distinct low-molecular colloid solution intended for enteral administration to facilitate detoxification within the gastrointestinal tract. This difference in application is linked to the functional versatility of the Povidone component itself.


What is the General Benefit of an Iodophor Antiseptic?

The general benefit of this type of medication is its ability to provide immediate and comprehensive anti-infective protection against various microorganisms. This is achieved through the sustained release microbicidal action of the free iodine, which rapidly acts to disrupt vital biological molecules within microbial cells through oxidation. This microbicidal mechanism is effective against a broad spectrum of organisms, including bacteria, viruses, fungi, and protozoa.

Consequently, the medicine’s overarching purpose is to help ensure the cleansing and purification of surface areas that are at risk of microbial contamination, supporting an environment less favorable to the growth of infection-causing agents.

What side effects are possible with Enterodes?

Possible side effects and safety information

The safety profile of this medicine, defined by its active ingredient Povidone Iodine, is documented in regulatory sources and primarily centers on the potential for systemic iodine absorption and localized adverse reactions. The greatest systemic safety consideration is the risk of endocrine disruption, specifically interference with thyroid function.

Officially Documented Adverse Reactions

Adverse reactions listed in official labels are categorized by the affected body system and frequency classification:

System-Organ Class Officially Documented Adverse Reactions Frequency Classification
Skin and Subcutaneous Tissue Disorders Local irritation; Hypersensitive skin reactions (e.g., pruritus, erythema); Contact dermatitis Rare (Hypersensitive skin reactions) Not Known
Immune System Disorders Hypersensitivity reactions; Anaphylactic reactions Not Known
Endocrine Disorders Abnormal thyroid function (hypothyroidism and hyperthyroidism) Not Known

Serious Safety Considerations and Constraints

Serious Adverse Reactions linked to significant systemic absorption (e.g., from large area application) include Acute Renal Failure, Metabolic Acidosis, and severe Anaphylactic Reactions.

Regulatory documentation establishes important Population-Specific Safety Constraints:

  • Thyroid Disorders: The medicine is explicitly contraindicated in individuals with hyperfunction of the thyroid (hyperthyroidism).
  • Newborns and Infants: There is an increased risk of developing hypothyroidism, necessitating caution.
  • Elderly Patients: Listed as being at increased risk of developing thyroid dysfunction.
  • Pregnancy and Lactation: Not recommended due to the potential for interference with fetal or neonatal thyroid function.

Risk is also tied to Duration of Exposure: Prolonged use or application over extensive areas can lead to notable iodine uptake and potential systemic effects. Furthermore, the application may interfere with thyroid function tests and other diagnostic procedures.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Enterodes (Povidone Iodine) presents with clinical signs primarily related to acute iodine toxicity. Documented manifestations include severe corrosive gastrointestinal symptoms such as abdominal pain, vomiting, and potentially bloody diarrhea, along with a burning sensation in the throat and a metallic taste in the mouth.

Mandated Emergency Action

Due to the risk of severe complications, government authorities mandate that individuals must seek immediate medical help and contact a Poison Control Center right away if an overdose is suspected. Urgent assistance is required for signs of severe, life-threatening outcomes, including circulatory collapse (shock), acute renal failure (anuria), and severe respiratory distress from laryngeal or pulmonary edema.

Management and Specific Risks

The established management protocol is defined as symptomatic and supportive, as regulatory documents state that no specific antidote is available. Hospitalization and intensive monitoring, including vital signs and ECG evaluation, are typically required. Additionally, specific risks are documented in vulnerable populations: new-born and small infants face a risk of hypothyroidism, and patients with preexisting thyroid disease are at risk of developing hyperfunction of the thyroid.

Therapeutic Uses of Enterodes

What Enterodes Treats: Main Uses and Benefits

This medicine provides supportive anti-infective management and specialized systemic detoxification, addressing two distinct therapeutic domains. The topical form is commonly used to address symptoms related to localized physical discomfort and the microbial load present in minor injuries. It is relevant for easing acute manifestations in cuts, abrasions, superficial burns, and surgical sites. Its application helps manage the early, visible signs of local contamination, including minor redness, swelling, and discharge. This contributes to improved day-to-day comfort during the healing phase.

The specialized enteral form, historically associated with Enterodes, is applied in clinical settings that involve acute or unstable symptom patterns characterized by systemic toxemia originating in the gastrointestinal tract. It is used for managing symptoms that create noticeable physiological strain, specifically severe, acute diarrhea and persistent vomiting. This approach provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.

“This medicine is relevant in contexts marked by increased discomfort or tension across acute therapeutic contexts.”

Quick Fact: Relief for Acute Systemic Symptoms The preparation is applied during phases of increased distress or discomfort associated with acute toxemia, helping to manage symptoms that interfere with daily comfort.

Regulatory References

  1. NIH DailyMed Drug Label for Povidone-Iodine

Eligibility and Restrictions for Use

Who Can and Cannot Use Enterodes?

Use of Enterodes (Povidone Iodine) is strictly governed by official population eligibility rules defined by health regulatory authorities.

Absolute Contraindications prohibit the use of this medicine in several groups. It must not be used by individuals with a known allergy or hypersensitivity to iodine or to any other component of the formulation. Use is also contraindicated for patients with a documented history of thyroid dysfunction or goitre. Due to the risk of systemic iodine absorption, the medicine is generally contraindicated in children below the age of two years, and specific formulations must not be used in infants under one month.

Use is Restricted for certain populations. The medicine is not recommended for regular use during pregnancy or lactation due to the potential for the active ingredient to affect the infant's thyroid. Special caution is advised for elderly patients and those with impaired renal function due to a heightened risk of iodine accumulation. Over-the-counter use is generally approved for adults and children 12 years of age and older. Use in children under 12 for non-prescription purposes requires consultation with a doctor.

What should I know about interactions with other medicines?

The interaction profile for Enterodes (Povidone Iodine) is defined by chemical incompatibility and the potential for systemic iodine load. Formal Regulatory Prohibitions strictly contraindicate co-administration with Mercury Derivatives due to the documented risk of forming caustic compounds. This combination must not be used.

Pharmacodynamic Interactions exist with systemic medications like Lithium. Concurrent use, especially if repeated or extensive, should be avoided as the systemic absorption of iodine may compound the risk of affecting the function of the thyroid gland. This caution is specific to patients taking Lithium and those with pre-existing thyroid dysfunction.

Chemical incompatibility necessitates avoiding co-administration with other antiseptics and detergents, Hydrogen Peroxide, and enzymatic wound treatments due to the potential for the inactivation or antagonism of the microbicidal effects. Regulatory documents also specify a timing restriction: Octenidine-containing antiseptics must not be used concomitantly or immediately after application to the same site.

Finally, the substance can interfere with diagnostic tests. This includes the potential for false-positive results in tests for occult blood or glucose in urine, and the systemic absorption of iodine can skew thyroid function test results.

Mechanism of Action

Non-Specific Oxidative Destruction of Pathogens

This primary mechanistic domain is defined by the action of free elemental iodine (I2), which is released from the polymer complex. The iodine rapidly engages in oxidation and iodination reactions with non-selective but vital microbial components, including enzymes, proteins, and cell membrane lipids, causing their immediate and irreversible inactivation. This chemical destruction of critical structures results in a fast and comprehensive alteration of microbial population size at the site of application.


Modulated Release and Luminal Sequestration

The mechanism is controlled by the Polyvinylpyrrolidone (Povidone) carrier, which functions as a sustained-release system by maintaining a dynamic equilibrium to slowly release I2. This kinetic control assists in preserving the drug's activity by maintaining a consistent free iodine concentration, thereby modulating host-cell exposure dynamics and sustaining the localized anti-microbial chemical potential.

Specific to certain enteral formulations, the non-absorbable Povidone polymer also utilizes a physical mechanism of non-specific adsorption. As a large colloid, it physically binds and traps pathogens and exogenous toxins in the gut lumen. The physiological consequence is the sequestration of luminal toxins and pathogens which physically impedes the free diffusion of bound substances across the gastrointestinal mucosa.

Dosage and Administration Information

The medicine Enterodes is officially administered through two distinct routes based on the product formulation. The globally recognized Topical application is used for anti-infective cleansing of skin and operative sites. The Oral/Enteral route applies to the specialized low-molecular colloid solution utilized for gastrointestinal detoxification protocols in accordance with regional regulatory guidance.

Topical solutions, such as the 7.5% or 10% strength, are applied functionally for either a single surgical preparation or multiple times daily for minor wounds. Procedural conditions mandate that the product is strictly for external use and must be allowed to air dry completely before any covering is applied. This antiseptic use is limited to a short course, typically not exceeding seven days.

The Enteral solution is administered in a divided regimen of three to four times daily, with the adult volume adjusted to the acute phase severity. A key administration rule is that the solution must be taken separately from food or any other oral medication, maintaining a one to two-hour interval. Dosing for pediatric patients requires specific, weight-based calculations detailed in the authorized prescribing information. Furthermore, caution is advised for use in individuals with pre-existing thyroid conditions.

Recent Clinical Evidence

Research evidence / Overview of studies for Enterodes

Evidence for Localized Anti-Infective Management (Topical Use)

This section will summarize the structure of the extensive research base, including numerous Randomized Controlled Trials (RCTs) and meta-analyses, that has explored the preparation's role as an antiseptic for skin and wound care, detailing the types of studies that examined outcomes such as Surgical Site Infection (SSI) rates.

The majority of research exploring Enterodes (Povidone Iodine) focuses on its application as a topical agent studied for its microbicidal characteristics. Studies conducted during periods of increased symptom activity, such as before and after surgical procedures, were the most common approach. These research efforts primarily examined whether the preparation was associated with measured changes in the incidence of Surgical Site Infection (SSI) and also tracked the rates of microbial count reduction on the skin surface. These studies involved adult patients undergoing a variety of operations, including general, orthopedic, and abdominal surgeries.

The studies reported measurements related to whether infection occurred in the days following a procedure. Some trials described patterns observed in the studied populations, noting that the preparation was observed in some studies to be associated with measured differences in infection rates compared to not using an antiseptic. When studies compared this preparation against other types of antiseptics, such as Chlorhexidine, the findings were sometimes mixed, with results varying depending on the specific type of surgery being evaluated. Findings also help contextualize how symptoms evolved in the observed populations, generally focusing on short-term outcomes related to the healing process.

Despite the large volume of research, long-term effects are not fully established. The primary infection rates measured in most studies focused on the short-term follow-up of around 30 days post-surgery. Comparative evidence is lacking consistency across all types of procedures, meaning the results apply only to the specific surgical populations studied. Furthermore, the evidence quality varies across studies due to differences in how the preparation was applied (e.g., solution versus scrub) and the severity of the wounds or surgical sites included.


Research on Systemic Detoxification (Enteral Use)

This part will review the research landscape for the historical association of the trade name with an enteral solution intended to address acute systemic toxemia originating in the gastrointestinal tract, noting the specific types of studies that are either available or missing from the authoritative scientific literature.

The specialized use of an Enterodes solution taken enterally (by mouth) for conditions presenting with cycles of stability and flare-ups, specifically acute diarrhea and persistent vomiting, is a topic where clinical trial research remains limited. Authoritative scientific and governmental sources do not currently reference high-quality, dedicated clinical trials, such as Randomized Controlled Trials (RCTs), that have specifically been conducted to study the preparation for this purpose. The absence of such evidence means there are no formal outcomes for this use that are consistently measured in regulator-cited research.

Because direct clinical evidence for this specific application is lacking, the preparation's action in managing outcomes related to systemic or functional imbalance has not been supported by definitive RCTs. Any related data primarily consists of research exploring systemic absorption of iodine and how this might influence thyroid biomarkers, which are outcomes related to physiological strain or stress rather than functional efficacy. Therefore, evidence is limited, and findings indicate a significant research gap in this area.


Long-Term Studies and Follow-up Durations

This area will outline the typical observation periods used in clinical studies, explaining what is known about outcomes measured over extended timeframes (beyond the immediate treatment phase) and what data exists regarding the durability or maintenance of the preparation's intended antiseptic action.

Most studies focusing on the preparation's antiseptic use have examined short-term symptom patterns. For example, in the context of preventing surgical infections, the critical follow-up durations were typically 30 days. This research provides context regarding short-term changes immediately after a procedure but offers limited information for long-term outcomes.

Studies that have monitored patients over longer defined time intervals, such as those lasting several months or years, are mainly designed to track very specific, delayed events, such as the relapse of certain infections or the continued maintenance of dental health in specific populations. However, these longer studies do not typically provide comprehensive data on the durability of the general antiseptic effect or patient-reported outcomes describing perceived discomfort over an extended timeframe, meaning long-term effects are not fully established.


Evidence in Specific Patient Groups and Vulnerable Populations

This section will describe what research, if any, has specifically evaluated the use of the preparation in distinct groups, such as children, older adults, or patients with specific comorbidities, where evidence may be limited or requires separate consideration.

Research efforts have predominantly focused on a general adult population undergoing routine surgical procedures. As a result, data for certain groups remain insufficient. While some studies have been applied in research contexts involving fluctuating or unstable symptoms in broader groups, evidence specific to children or older adults in general wound care is not as extensively detailed or consistent as the data for the main surgical population.

Furthermore, comparative evidence is lacking specifically for how the preparation is observed in patients with significant comorbidities—conditions marked by functional limitations and physiological strain. Therefore, research provides context but not individual predictions for how these specific groups may respond, and certainty remains low in these areas.


What is Still Uncertain About Enterodes

This final part will synthesize the key evidence gaps identified across the research base, clarifying areas such as inconsistent findings in comparative trials, the absence of dedicated clinical trials for the specialized enteral use, and other areas where further research is needed.

A primary area of uncertainty involves the specialized enteral use for systemic symptoms; the absence of high-quality RCTs means the evidence base for this application is limited. Research does not determine whether an individual will respond similarly when using the product in this manner, and this application is associated with a fundamental research gap.

Even in the well-studied topical context, results apply only to the populations studied, and comparative evidence is lacking in some contexts; findings were mixed when comparing the preparation to alternatives in certain surgical types. Subgroup findings are uncertain, and while the agent was studied for numerous applications, the quality and consistency of the evidence varies across studies.

Frequently Asked Questions (FAQ)

Common questions about Enterodes (FAQ)

Q: Can I stop taking Enterodes once my blood pressure is normal?

Stopping a prescribed medication should only be done under a healthcare provider's direction. Official labeling and general medical practice emphasize the importance of continuous treatment for high blood pressure, even if blood pressure appears normal. Suddenly discontinuing medication for high blood pressure can carry risks, as it may lead to a rapid increase in blood pressure. Patients are advised to always discuss any potential dosage adjustments with their prescribing healthcare provider.


Q: Does Enterodes cause weight gain?

Enterodes is generally considered weight-neutral. Weight changes are not commonly listed as a typical side effect in the official prescribing information for Enterodes. If you are concerned about any side effects, including weight changes, it is best to consult your doctor. Enterodes is prescribed to manage blood pressure, and patients should discuss the expected benefits and potential risks with their doctor.


Q: What is the best time of day to take my Enterodes?

Enterodes is generally prescribed as a once-daily medication. To ensure consistent blood levels, it's often recommended to take the dose at the same time each day. Some prescribers may recommend taking it in the morning, though patients should follow the specific instructions provided by their healthcare provider. The medication can be taken with or without food, as noted in the product label.

How should Enterodes be stored and disposed of?

The official regulatory guidelines for Enterodes, which contains Povidone Iodine, define strict conditions for storage and disposal to maintain product quality.

Storage Requirements

Temperature and Environment: The product must be stored below 25°C (77°F) at controlled room temperature. It is mandatory to protect from light and excessive heat.

Handling Constraints: Do not freeze the solution. The product must remain in its original container, which must be kept tightly closed when not in use.

Safety: Like all medicines, it must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product must be disposed of according to local regulations. Utilize a drug take-back program if available, as this is the preferred method. The solution should not be released to the environment or discarded into sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enterodes found in:

A-Z Index: